Wolf H Fridman

List of Publications by Year
in descending order

46 papers	10,038 citations	117453 34 h-index	243296 44 g-index
48 all docs	48 docs citations	48 times ranked	13552 citing authors

#	Article	IF	Citations
1	Estimating theÂpopulation abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biology, 2016, 17, 218.	3.8	1,980
2	The immune contexture in cancer prognosis and treatment. Nature Reviews Clinical Oncology, 2017, 14, 717-734.	12.5	1,590
3	B cells are associated with survival and immunotherapy response in sarcoma. Nature, 2020, 577, 556-560.	13.7	1,158
4	PD-1â€“Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer. Cancer Research, 2013, 73, 128-138.	0.4	554
5	Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers. Clinical Cancer Research, 2006, 12, 465-472.	3.2	517
6	The same tyrosine-based inhibition motif, in the intra-cytoplasmic domain of FcÎ³RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity, 1995, 3, 635-646.	6.6	425
7	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clinical Cancer Research, 2015, 21, 3031-3040.	3.2	355
8	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Frontiers in Immunology, 2020, 11, 784.	2.2	339
9	Interleukin-17 inhibits tumor cell growth by means of a T-cellâ€“dependent mechanism. Blood, 2002, 99, 2114-2121.	0.6	309
10	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 4416-4428.	3.2	252
11	Differential Modulation of Stimulatory and Inhibitory FcÎ³ Receptors on Human Monocytes by Th1 and Th2 Cytokines. Journal of Immunology, 2001, 166, 531-537.	0.4	215
12	Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. Current Topics in Microbiology and Immunology, 2010, 344, 1-24.	0.7	193
13	A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients. Journal of Immunotherapy, 2010, 33, 991-998.	1.2	188
14	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nature Reviews Clinical Oncology, 2022, 19, 441-457.	12.5	176
15	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer, 2021, 2, 794-802.	5.7	173
16	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Advances in Immunology, 2016, 130, 95-190.	1.1	160
17	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. Cancer Immunology Research, 2019, 7, 1091-1105.	1.6	153
18	Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated FcÎ³RIIB during negative regulation of IgE-dependent mouse mast cell activation. Immunology Letters, 1996, 54, 83-91.	1.1	121

#	Article	IF	Citations
19	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. OncoImmunology, 2012, 1, 326-333.	2.1	95
20	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunology, Immunotherapy, 2018, 67, 981-988.	2.0	89
21	Molecular Basis of the Recruitment of the SH2 Domain-containing Inositol 5-Phosphatases SHIP1 and SHIP2 by FcÎ³RIIB. Journal of Biological Chemistry, 2000, 275, 37357-37364.	1.6	84
22	The Soluble Î± Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer. Cancer Research, 2008, 68, 3907-3914.	0.4	75
23	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Medicine, 2020, 12, 86.	3.6	63
24	Signal Regulatory Proteins Negatively Regulate Immunoreceptor-dependent Cell Activation. Journal of Biological Chemistry, 1999, 274, 32493-32499.	1.6	61
25	Complement System: Promoter or Suppressor of Cancer Progression?. Antibodies, 2020, 9, 57.	1.2	58
26	B Subunit of Shiga Toxin-Based Vaccines Synergize with Î±-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity. Journal of Immunology, 2007, 179, 3371-3379.	0.4	55
27	Therapeutic Targeting of the Colorectal Tumor Stroma. Gastroenterology, 2020, 158, 303-321.	0.6	51
28	Better understanding tumorâ€“host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head and Neck, 2010, 32, 946-958.	0.9	50
29	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. Frontiers in Oncology, 2018, 8, 390.	1.3	46
30	Two Distinct Tyrosine-based Motifs Enable the Inhibitory Receptor FcÎ³RIIB to Cooperatively Recruit the Inositol Phosphatases SHIP1/2 and the Adapters Grb2/Grap. Journal of Biological Chemistry, 2004, 279, 51931-51938.	1.6	45
31	Distinct intracytoplasmic sequences are required for endocytosis and phagocytosis via murine FcÎ³RII in mast cells. International Immunology, 1993, 5, 1393-1401.	1.8	44
32	Insufficient Phosphorylation Prevents FcÎ³RIIB from Recruiting the SH2 Domain-containing Protein-tyrosine Phosphatase SHP-1. Journal of Biological Chemistry, 2001, 276, 6327-6336.	1.6	43
33	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunology Research, 2021, 9, 891-908.	1.6	43
34	Negative regulation of mast cell proliferation by FcÎ³RIIB. Molecular Immunology, 2002, 38, 1295-1299.	1.0	40
35	Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer. Journal of Clinical Oncology, 2009, 27, e5-e6.	0.8	36
36	Receptors for immunoglobulin isotypes (FcR) on murine T cells: I. Multiple FcR expression on T lymphocytes and hybridoma T cell clones. European Journal of Immunology, 1985, 15, 662-667.	1.6	33

#	Article	IF	Citations
37	The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human FcÎ³RIIB and is mandatory for negative regulation of B cell activation. Immunology Letters, 2006, 104, 156-165.	1.1	30
38	Immune-based identification of cancer patients at high risk of progression. Current Opinion in Immunology, 2018, 51, 97-102.	2.4	29
39	Src Homology 2 Domain-containing Inositol 5-Phosphatase 1 Mediates Cell Cycle Arrest by FcÎ³RIIB. Journal of Biological Chemistry, 2001, 276, 30381-30391.	1.6	27
40	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 643065.	1.3	26
41	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 463-474.	1.4	16
42	Cytokines and cell regulation. Molecular Aspects of Medicine, 1997, 18, 1-90.	2.7	14
43	Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. Oncologist, 2022, 27, 501-511.	1.9	14
44	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Frontiers in Immunology, 2011, 2, 66.	2.2	9
45	SHIP1-mediated negative regulation of cell activation and proliferation by FcÎ³RIIB. , 2001, , 141-152.		0
46	Les structures lymphoÃ¯des tertiaires gÃ©nÃ¨rent et propagent des plasmocytes produisant desÂanticorps antitumoraux dans le cancer du rein. Medecine/Sciences, 2022, 38, 536-538.	0.0	0